Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945912 | 0.84 | GABRA1 (0.45) | TSHRKMT2AKCNK3KCNK9HPGD | |
| SCHEMBL20327219 | 0.84 | TSHR (0.31) | TSHRHPGDLMNA | |
| SCHEMBL6242550 | 0.84 | TSHR (0.53) | TSHRKMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL29723345 | 0.84 | TSHR (0.53) | TSHRKMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL14523913 | 0.83 | LMNA (0.43) | TSHRKMT2ACES2CES1PDK2 | |
| SCHEMBL23995818 | 0.82 | KMT2A (0.36) | TSHRKMT2ACES2CES1BRPF1 | |
| SCHEMBL21132416 | 0.82 | CES2 (0.42) | KMT2ACES2CES1PDK2THRB | |
| SCHEMBL23590675 | 0.80 | TSHR (0.31) | TSHRHPGDLMNA | |
| SCHEMBL29841597 | 0.79 | LMNA (0.47) | TSHRKMT2AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL19611955 | 0.79 | LMNA (0.47) | TSHRKMT2AKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4081521-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LTD (IN) | 2025-12-10 | — | — | EP | disclosed |
| US-20250270220-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12304915-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-05-20 | — | — | US | disclosed |
| CN-119948027-A | SOS1 protein degradation agent and application thereof | 领泰生物医药(绍兴)有限公司 | 2025-05-06 | — | — | CN | disclosed |
| EP-4543450-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119546304-A | Salts of SOS1 inhibitors | 米拉蒂治疗公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20250059182-A1 | SOS1 INHIBITORS | MIRATI THERAPEUTICS, INC | 2025-02-20 | — | — | US | disclosed |
| CN-119462626-A | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-115135315-B | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-115605476-A | Substituted tricyclic compounds | 鲁宾有限公司（IN） | 2023-01-13 | — | — | CN | disclosed |
| EP-4081521-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | Lupin Limited (IN) | 2022-11-02 | — | — | EP | disclosed |
| CN-115135315-A | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| WO-2022026465-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-02-03 | — | — | WO | disclosed |
| US-20210188857-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| US-20210177851-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-06-17 | — | — | US | disclosed |
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-01-14 | — | — | US | disclosed |
| WO-2020254451-A1 | ANTICANCER COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-24 | — | — | WO | disclosed |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOST, SOS2 | TSHR 2308/4885KMT2A 3577/4885CES2 4617/4885 |
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | SOS1, SOS2, SOST | TSHR 3559/4885KMT2A 3165/4885CES2 3989/4885 |
| US-12304915-B2 | SOS1 inhibitors | SOS1, SOS2, SAV1 | TSHR 3357/4885KMT2A 3283/4885CES2 4258/4885 |
| US-20250059182-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | TSHR 3618/4885KMT2A 3302/4885CES2 4247/4885 |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOST, SOS2 | TSHR 2311/4885KMT2A 3605/4885CES2 4627/4885 |
| US-20250270220-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | TSHR 3357/4885KMT2A 3283/4885CES2 4258/4885 |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | SOS1, SOST, BMP1 | TSHR 2697/4885KMT2A 3027/4885CES2 4654/4885 |
| US-20210188857-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | TSHR 3618/4885KMT2A 3302/4885CES2 4247/4885 |
| US-20210177851-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOS2, SOST | TSHR 2962/4885KMT2A 3346/4885CES2 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.